Ceyoka (private) Limited

Ceyoka (Private) Limited, established in 1985, is a diversified Sri Lankan company headquartered at 55 Negombo Road, Peliyagoda, Sri Lanka. Over the past four decades, Ceyoka has played a pivotal role in the nation's development by supplying goods and services to both public and private sectors. The company's diversified activities encompass trading, healthcare, essential oils and flavors, and commercial air conditioning.

Within the healthcare sector, Ceyoka Health is recognized as a leading supplier of pharmaceuticals, medical devices, and surgical equipment to both government and private institutions in Sri Lanka. The company has achieved industry firsts, including introducing advanced needle-free technology and offering dialysis services in collaboration with Fresenius Medical Care. (ft.lk) Additionally, Ceyoka has expanded its portfolio by becoming the exclusive distributor for Eurofarma, a prominent Brazilian pharmaceutical company, in 2015. (ft.lk)

Ceyoka's distribution network is strategically designed to ensure nationwide coverage across Sri Lanka. The company's headquarters in Peliyagoda serve as the central hub for its operations. While specific warehouse locations are not publicly disclosed, Ceyoka's extensive sales and service network facilitates efficient logistics and timely delivery of products to various regions within the country. This infrastructure supports the company's role as a key supplier of pharmaceuticals, medical devices, and other products to both government and private sector institutions.

Ceyoka (Private) Limited holds a significant position in Sri Lanka's pharmaceutical supply chain as a primary wholesaler and distributor. The company imports a diverse range of pharmaceutical products, including advanced antifungals, antifungals, and antibiotics, catering to various therapeutic needs. Ceyoka Health, a division of the company, is recognized as a leading supplier of pharmaceuticals, medical devices, and surgical equipment to both government and private sector institutions in Sri Lanka. This extensive involvement underscores Ceyoka's integral role in ensuring the availability of essential healthcare products across the nation.

Ceyoka's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.6 million USD from India over 45 shipments, primarily sourced from three Indian suppliers:

• LEBEN LABORATORIES PRIVATE LIMITED: $1.9 million USD (95.4% of shipments)
• GALENTIC PHARMA INDIA PRIVATE LIMITED: $79,000 USD (3.9% of shipments)
• BHARAT SERUMS AND VACCINES LIMITED: $15,000 USD (0.7% of shipments)

This concentration suggests a strategic choice to maintain strong relationships with select suppliers, potentially ensuring favorable terms and consistent product quality. However, the heavy reliance on a single supplier, LEBEN LABORATORIES PRIVATE LIMITED, which accounts for 95.4% of shipments, introduces a risk of supply chain disruption in the event of issues with this supplier. The stability of this relationship is crucial for Ceyoka's operations, and any disturbances could significantly impact the company's ability to meet market demand.

Ceyoka's supply chain resilience is closely tied to its sourcing strategy. The heavy reliance on LEBEN LABORATORIES PRIVATE LIMITED for the majority of its imports indicates a potential vulnerability. While the company imports a diverse range of formulations (353 unique formulations), the limited number of suppliers suggests a lack of diversification in sourcing. This concentration could pose challenges in maintaining a steady supply of products, especially if alternative suppliers are not readily available. Additionally, the exposure to shipping routes and potential regulatory changes in India could further impact the supply chain's stability. Ensuring compliance with regulatory standards and maintaining robust relationships with existing suppliers are essential for mitigating these risks.

Ceyoka's sourcing pattern, characterized by a high concentration of imports from a single supplier, positions the company to leverage strong supplier relationships and potentially secure favorable terms. However, this strategy also exposes Ceyoka to significant risks associated with supply chain disruptions. For Indian exporters, this presents an opportunity to diversify their customer base by offering alternative products or formulations that align with Ceyoka's existing portfolio. By addressing potential gaps in Ceyoka's current sourcing strategy, Indian exporters can position themselves as viable alternatives, thereby enhancing their market presence in Sri Lanka.

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. The NMRA operates under the Medicines (Pricing Mechanism for Medicines) Regulations, which grant it explicit authority to impose and control prices for all medicines in the country. All pharmaceutical products imported into Sri Lanka must be registered with the NMRA and obtain approval before distribution or sale. This process ensures that imported medicines meet the country's quality, safety, and efficacy standards. (nmra.gov.lk)

Import licensing is a critical component of Sri Lanka's pharmaceutical import regulations. Applications for import licenses must be submitted to the NMRA, accompanied by necessary documentation, including evidence of previous importation and participation in tenders. As of February 2026, the NMRA has introduced new requirements for price submissions, particularly for import licenses expiring on or after 1st February 2026. Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards. The NMRA recognizes GMP certificates from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition ensures that imported medicines adhere to internationally accepted quality standards. (nmra.gov.lk)

Quality assurance is paramount in Sri Lanka's pharmaceutical import regulations. Imported medicines must undergo batch testing to verify their quality, safety, and efficacy. Stability requirements ensure that products maintain their intended quality throughout their shelf life. Labeling must be in the Sinhala language, and labels must include the Maximum Retail Price (MRP), the name and address of the local Marketing Authorization Holder (MAH) or importer, and other pertinent information. These requirements aim to provide consumers with clear and accurate information about the medicines they use. (softgroup.eu)

Between 2024 and 2026, the NMRA implemented several policy changes affecting pharmaceutical imports into Sri Lanka. Notably, from 1st January 2025, all import data for pharmaceuticals and manufacturing data from local manufacturers must be submitted in a specified format to the Market Control Division of the NMRA. (nmra.gov.lk) Additionally, as of 31st December 2025, all imported finished pharmaceutical products must carry a price-marked label before being released to the local market. This label must clearly display the MRP and the name and address of the local MAH or importer. (softgroup.eu) These changes aim to enhance transparency, pricing control, and accountability in the pharmaceutical supply chain.

Ceyoka's product strategy focuses on importing and distributing a range of pharmaceutical products, including advanced antifungals, antifungals, and antibiotics. The company's portfolio is heavily concentrated in the advanced antifungal category, which constitutes 54.4% of its imports, followed by antifungals at 27.2%, and antibiotics at 18.3%. This focus aligns with the market demand for effective treatments in these therapeutic areas. The high import values of specific products, such as Griseofulvin ($891K) and Miconazole ($445K), indicate a strategic emphasis on these medications. The demand for these products is likely driven by the prevalence of fungal infections and the need for effective antifungal therapies in the Sri Lankan market.

Ceyoka's sourcing strategy is characterized by a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. The company imports finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. This approach suggests a preference for ready-to-market products that meet the regulatory standards of Sri Lanka. The reliance on a limited number of suppliers, particularly LEBEN LABORATORIES PRIVATE LIMITED, indicates a strategic choice to maintain strong supplier relationships, though it also introduces potential risks associated with supply chain disruptions.

Based on its product mix, Ceyoka (